Could a cell shot free CML patients from daily pills?
NCT ID NCT07651878
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a cell therapy called vididencel in 24 adults with chronic myeloid leukemia (CML) who still have traces of cancer despite taking standard medication. The goal is to see if adding vididencel to their current treatment is safe and might eventually allow them to lower or stop their daily pills. Participants receive injections over several months and are followed for up to 3 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vididencel (a cell therapy made from donor cells)
- What this could lead to
- If it works, this could help some CML patients reduce or stop their daily TKI medication without the cancer returning.
- What could go wrong
- This is a very early Phase 1 trial with only 24 participants, so it may not work or could have side effects. Participants may not benefit directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CML (CHRONIC MYELOGENOUS LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Haukeland University Hospital
RECRUITINGBergen, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.